Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines

Inflammatory Bowel Diseases

Volumn 18, Issue 2, 2012, Pages 261-268

  Dotan, Iris ^a   Werner, Lael ^a   Vigodman, Sharon ^a   Agarwal, Shradha ^b   Pfeffer, Jorge ^a   Horowitz, Noya ^a   Malter, Lisa ^b   Abreu, Maria ^b   Ullman, Thomas ^b   Guzner Gur, Hanan ^a   Halpern, Zamir ^a   Mayer, Lloyd ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; immune response; immunomodulators; ulcerative colitis

Indexed keywords

AZATHIOPRINE; DIPHTHERIA TETANUS TOXOID; INFLUENZA VACCINE; MERCAPTOPURINE; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE COUNT; MALE; MIDDLE AGED; VACCINES; YOUNG ADULT;

EID: 84855708317     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21688     Document Type: Article

References (26)

1. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980; 302: 981-987. (Pubitemid 10125406)
2. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; 1: CD000067.
3. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007; 102: 2488-2494. (Pubitemid 47631795)
4. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003; 111: 1133-1145. (Pubitemid 36519931)
5. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34: 1081-1085. (Pubitemid 23245359)
6. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118: 1025-1030. (Pubitemid 30346978)
7. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929-936. (Pubitemid 351451967)
8. Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005; 39: 21-26. (Pubitemid 40041338)
9. Aberra FN, Lichtenstein GR,. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 685-695. (Pubitemid 40961083)
10. Korelitz BI, Fuller SR, Warman JI, et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 1999; 94: 424-426. (Pubitemid 29084663)
11. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 677-692. (Pubitemid 39276481)
12. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2009; 3: 47-91.
13. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101: 1834-1840. (Pubitemid 44166594)
14. Kapetanovic MC, Saxne T, Sjöholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006; 45: 106-111. (Pubitemid 43033885)
15. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 148-154.
16. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
17. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629. (Pubitemid 18010466)
18. Stone KD, Feldman HA, Huisman C, et al. Analysis of in vitro lymphocyte proliferation as a screening tool for cellular immunodeficiency. Clin Immunol. 2009; 131: 41-49.
19. Pacheco SE, Shearer WT,. Laboratory aspects of immunology. Pediatr Clin North Am. 1994; 41: 623-655. (Pubitemid 24249432)
20. Gouni-Berthold I, Baumeister B, Berthold HK, et al. Ig and IgG subclasses in patients with inflammatory bowel disease. Hepatogastroenterology. 1999; 46: 1720-1723. (Pubitemid 29366331)
21. Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004; 33: 283-288. (Pubitemid 38280827)
22. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002; 34: 147-153. (Pubitemid 34028344)
23. Noroski LM, Shearer WT,. Screening for primary immunodeficiencies in the clinical immunology laboratory. Clin Immunol Immunopathol. 1998; 86: 237-245. (Pubitemid 28169454)
24. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 851-856. (Pubitemid 47031059)
25. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 444-453.
26. Ben-Horin S, Goldstein I, Fudim E, et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut. 2009; 58: 396-403.